MIRA INFORM REPORT

 

 

 

 

Report Date :

20.01.2013

 

IDENTIFICATION DETAILS

 

Name :

LABORATORIOS ALMOS S.A.

 

 

Registered Office :

Avda. Defensores del Chaco 836, Fernando de la Mora

 

 

Country :

Paraguay

 

 

Date of Incorporation :

1973

 

 

Legal Form :

Public Limited Company

 

 

Line of Business :

Medical Laboratory Specialties

 

 

No. of Employees :

150

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Paraguay

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

portugal - ECONOMIC OVERVIEW

 

Portugal has become a diversified and increasingly service-based economy since joining the European Community - the EU's predecessor - in 1986. Over the past two decades, successive governments have privatized many state-controlled firms and liberalized key areas of the economy, including the financial and telecommunications sectors. The country qualified for the Economic and Monetary Union (EMU) in 1998 and began circulating the euro on 1 January 2002 along with 11 other EU members. The economy had grown by more than the EU average for much of the 1990s, but fell back in 2001-08, and contracted 2.5% in 2009, before growing 1.3% in 2010. But GDP fell again in 2011, as the government implemented austerity measures, including a 5% public salary cut, a 2% increase in the value-added tax, and an extraordinary tax on yearend bonuses to comply with conditions of an EU-IMF financial rescue package agreed to in May 2011. GDP per capita stands at roughly two-thirds of the EU-27 average. A rigid labor market has been an obstacle to greater productivity and growth. Portugal also has been increasingly overshadowed by lower-cost producers in Central Europe and Asia as a destination for foreign direct investment. Portugal's low competitiveness, low growth prospects, and high levels of public debt have made it vulnerable to bond market turbulence. The government reduced the budget deficit from 10.1% of GDP in 2009 to 4.5% in 2011, an achievement made possible only by the extraordinary revenues obtained from the one-time transfer of bank pension funds to the social security system. Investors, however, continue to express concern about the government's ability to achieve future budget deficit targets and obtain foreign financing to cover its sovereign debt obligations when the EU-IMF financing program expires in 2013. Without the option for stimulus measures, the government is focusing instead on boosting exports and implementing labor market and other structural reforms to try to raise GDP growth and increase Portugal's competitiveness - which, over time, may help mitigate investor concerns.         

Source : CIA


Registered Name 

 

LABORATORIOS ALMOS S.A.

RUC Nº 80029411-4

 

 

Summary 

 

BEGINNER OF ACTIVITIES. INCORPORATED IN 1973. NOT PROVIDED BALANCE SHEET. NO NEGATIVE. FIT FOR OPERATIONS OF MODERATED IMPORTANCE AND ADDITIONAL GUARANTEES.

 

 

Operations 

 

MEDICAL LABORATORY SPECIALTIES.
REPRESENTATIONS.

 

 

Legal Structure 

  

LEGAL FORM:              PUBLIC LIMITED COMPANY
CREATED:                    1973
REGISTERED RPC:     1973
DURATION:                   UNLIMITED
END OF FISCAL YEAR: 31.12

 

 

Contact 

  

Legal and dependences operatives centrals address:
--------------------------------------------------
Avda. Defensores del Chaco 836, Fernando de la Mora, Republic of Paraguay.

Phone. 595-21 512936
Fax. 595-21 505536
E.Mail: info@laboratoriosalmos.com.py
Web:    www.laboratoriosalmos.com.py

 

 

Partners 

 

PRESIDENT:                             JULIAN APODACA
GENERAL MANAGER:              EMILIO GUERRERO

ACCOUNTANT:                         RUTH PICCO

Using signature: It is in charge of the first two mentioned.

 

 

History 

 

Society as a comment is the initiator of the activities concerned. It was founded in 1973 and is dedicated to the manufacture and distribution of pharmaceutical products.

Is currently considered one of the most prestigious laboratories operating in the Republic of Paraguay.

Founded in 1973 in Asuncion, and began with the distribution abricacion an interesting line of pharmaceutical products. They are leaders in the pharmaceutical market.

 

 

Economic-Financial Position 

  

Ms. Lorena Ojeda, in charge of administration, confirm that not provided financial information to third parties.

Inquiries made ??through third parties have determined that it operates within a reasonable area of ??economic importance, with normal management to present and obtaining compensation benefits.

They close their exercises at 31.12.

 

 

Assets 

  

REAL ESTATE:
------------

- Avda. Defensores del Chaco 836, Fernando de la Mora, Republic of Paraguay.

- Acceso Sur 8569 km. 20 Ypane, Paraguay.

VEHICLES:
---------

It has several vehicles of various characteristics, affected the development of operations.

 

 

Evolution and Results 

 

Operates within the lines above, having made ??the necessary infrastructure.

With 150 employees who collaborate in the care of different tasks.

Imports from Argentina and Switzerland, while its sales are limited to the domestic market.

HABITUAL SUPPLIERS:
-------------------
ITALQUIMICA S.A. (PARAGUAY)
REDOX S.A. (PARAGUAY)

* 150 EMPLOYEES.

 

 

Branches 

 

Plant of production:
--------------------
Acceso Sur 8569 km. 20 Ypane, Paraguay.

 

 

Payment Record and Credit Risk 

  

BANCO CONTINENTAL
BANCO REGIONAL
INTERBANCO

Branch. F. de la Mora.

INSURAN
CE:
----------
MAPFRE S.A.

 

 

Concept 

 

Until present day it doesn't register negative records that could affect its concept.  

* FULFILLMENT: WITHOUT OBJECTIONS

 

 

Final Opinion 

  

This was all that could be registered about the company, who has a very good importance on its sector. Its credit relation is feasible, although for amounts of moderated importance with additional guarantees.  

* FIT FOR OPERATIONS OF MODERATED IMPORTANCE.  

NOTE: They were told that information is requested by PHARMAPACK ACG (INDIA) but not provided balance sheet.

 

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.54.94

UK Pound

1

Rs.86.24

Euro

1

Rs.72.20

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.